BioMed Research International

BioMed Research International / 2019 / Article

Review Article | Open Access

Volume 2019 |Article ID 4569826 | 15 pages | https://doi.org/10.1155/2019/4569826

Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast

Academic Editor: Francesco Del Galdo
Received01 Nov 2018
Revised18 Dec 2018
Accepted02 Jan 2019
Published23 Jan 2019

Abstract

Systemic sclerosis (SSc) is a complex rheumatologic autoimmune disease in which inflammation, fibrosis, and vasculopathy share several pathogenic pathways that lead to skin and internal organ damage. Recent findings regarding the participation and interaction of the innate and acquired immune system have led to a better understanding of the pathogenesis of the disease and to the identification of new therapeutic targets, many of which have been tested in preclinical and clinical trials with varying results. In this manuscript, we review the state of the art of the pathogenesis of this disease and discuss the main therapeutic targets related to each pathogenic mechanism that have been discovered so far.

1. Introduction

Systemic sclerosis (SSc) is a systemic autoimmune disease in which inflammation and fibrosis play a crucial role and lead to severe damage and failure of multiple organs such as the skin, joints, tendons, gastrointestinal tract, lungs, heart, blood vessels, and kidneys. It primarily affects women (female:male ratio of 4:1-10:1, depending on age and ethnicity) [1, 2], and there are 2 clinical subsets according to the extent of skin involvement: diffuse cutaneous SSc (dcSSc) (skin damage proximal to elbows and/or knees or that affects thorax and/or abdomen at any given time during the disease) and limited cutaneous SSc (lcSSc) (skin damage distal to elbows and knees without involvement of either thorax or abdomen). This disease may lead to major disabilities due to vascular complications, cardiopulmonary involvement, inflammatory myopathy, and arthritis; likewise, it can cause malnutrition due to gastrointestinal tract involvement, and it can decrease quality of life as a consequence of the psychological and social impact. Additionally, it can be fatal, with a 3-year survival rate of 47-56% in cases of serious pulmonary or cardiac involvement, particularly PAH [35]; in fact, it is the single connective tissue disease with the worst survival prognosis [1].

Groups of experts have tried to come to a consensus regarding treatment for specific organ involvement. Such is the case of EULAR’s recommendations for the treatment of systemic sclerosis, which aims to guide treatment for patients based on evidence and clinical experience from worldwide experts; however, there is still no standardized and effective treatment for this disease to date [2].

The understanding of the pathogenesis of the disease has improved considerably in recent years. Although there are still many unanswered questions, the participation of the immune response cells and inflammatory mediators, fibroblasts, and other components of the extracellular matrix and the central role of endothelial damage have changed the paradigm of this disease that was previously considered as predominantly fibrotic. Now it is conceived as a complex syndrome with multiple pathogenic pathways that may be treated simultaneously.

In recent years, there has been substantial progress in the management of some complications developed by these patients, which has led to increased disease survival and quality of life. This includes better control of complications in specific organs (such as interstitial lung disease, pulmonary arterial hypertension, renal crisis, and Raynaud’s phenomenon) as well as standardized follow-up and earlier detection of potential complications [6].

The ideal of “targeted therapy” will be an increasingly attainable objective insofar as our understanding of the disease improves. As stated by Dr. Denton [4], this concept in systemic sclerosis can have different meanings: the first one refers to the treatment of specific organ complications such as renal crises, interstitial lung disease, and pulmonary arterial hypertension; the second one refers to the treatment of symptoms of a determined organ involvement such as Raynaud’s phenomenon or gastroesophageal reflux; the third one refers to the treatment of individual disease processes such as immune activation, inflammation, fibrosis, or vasculopathy; and the last one refers to the blocking of certain cell types or interactions between cells that impact on various aspects of the disease through the same mechanism, even and ideally blocking an intracellular target or a specific pathway that modifies several pathological processes of the disease. Many molecules involved in the pathogenesis of this disease have been evaluated as therapeutic targets in preclinical and clinical trials with diverse outcomes (Tables 1 and 2) [7]. Here we present the state of the art of the pathogenic pathways and proposed targeted therapies.


Proposed therapy Target

VASCULAR
 (i) Bosentan, macitentan receptor
 (ii) Ambrisentan receptor
 (iii) SelexipagIP receptor agonist
 (iv) RiociguatGMPc agonist
 (v) Methyl bardoxoloneNrf2 and NF-kB

INFLAMMATION
 (i) AnifrolumabType I IFN
 (ii) Sifalimumab, RontalizumabType I IFN
 (iii) MEDI7734Anti-ILT7
 (iv) RituximabCD20
 (v) BasiliximabIL-2Rα
 (vi) EfalizumabLFA1/ICAM-1
 (vii) AbataceptCTLA4
 (viii) αMSH, IL10, CCL2
 (ix) TocilizumabIL-6R
 (x) AM095, SAR100842LPA1
 (xi) TAK242TLR4
 (xii) InebilizumabAnti-CD19

FIBROSIS
 (i) Imatinib, Dasatinib, Nilotinibc-Abl, c-Kit, PDGF
 (ii) CAT-192TGFβ1
 (iii) GC-1008TGFβ1,-β2,-β3
 (iv) FG-3019CCN2
 (v) P144TGFβ1
 (vi) Anti-Integrin αVβ6TGFβ activation
 (vii) PirfenidoneTNFα, IL1β, TGFβ
 (viii) NintedanibVEGF, PDGF, FGF

Note: ET, endothelin; IP, G protein-coupled receptor; cGMP, cyclic guanosine monophosphate; TNF-α, tumor necrosis factor alpha; IL, interleukin; CCR2, chemokine receptor type 2; LFA1, lymphocyte function-associated antigen 1; ICAM-1, intercellular adhesion molecule 1; CTLA-4, cytotoxic T-lymphocyte antigen 4; αMSH, alpha-melanocyte stimulating hormone; CCL2, chemokine (C-C motif) ligand 2; LPA1, lysophosphatidic acid 1; c-Abl, cellular oncogene homologous to Abelson's murine leukemia; c-Kit, proto-oncogene tyrosine kinase; PDGF, platelet-derived growth factor; TGF, transforming growth factor; CCN2, type 2 connective tissue growth factor; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; Nrf2: nuclear factor erythroid derived 2-related factor 2; NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells.

Drug nameTargetMechanism of actionTrial ID/reference

Treatments against immune mediators

Anifrolumab
(MEDI546)
Directed against subunit 1 of type I interferon receptorDownregulation of T-cell activationNCT00930683

Inebilizumab (MEDI551)Anti-CD19Depletion of B cells through enhanced antibody-dependent cellular cytotoxicityNCT00946699

Sifalimumab
Rontalizumab
Anti-IFNαSpecific for IFNα blocking; doesn’t neutralize other type I IFNsNCT01283139
NCT00541749

MEDI7734Anti-ILT7Temporary depletion of plasmacytoid dendritic cellsNCT02780674

RituximabAnti-CD20Targets CD20 expressed from pre-B cell stage to the pre-plasma cell stageGiuggioli D et al. [10]

BasiliximabAnti-IL-2RαDirected against the α chain (CD25) of the IL-2 receptorBecker MO et al. [11]

EfalizumabLFA1/ICAM-1Interaction between LFA-1 and ICAM-1 is blocked, preventing T-cell’s activationZimmerman T et al. [12]

AbataceptCTLA4Inhibits T-cell activation by selectively modulating costimulation (binds to CD80 or CD86 on cell surface)Elhai M et al. [13]

AIMSPRO (®)αMSH, IL10, CCL2Modulates serum levels of relevant cytokinesQuillinan NP et al. [14]

TocilizumabIL-6RRegulatory effect in the balance between Th17 and TregsNCT01532869

AM095 and SAR100842LPA1Targets specific G-protein-coupled receptorsNCT01651143

TAK242TLR4Prevents Th1 and Th17 cytokines production by inhibiting TLR4 stimulationBhattacharyya S et al. [15]

Treatments against Fibrosis

ImatinibPDGF, TGF-βBlocks both PDGF and TGF-β signalling pathwaysIwamoto N et al. [16]

Dasatinib,
Nilotinib
c-Abl, PDGFSecond-generation TKIs with higher affinity to Bcr-AblAkhmetshina A et al. [17]

Metelimumab (CAT-192)TGFβ1Specifically counteracts the TGFβ1 isoformDenton CP et al. [18]

Fresolimumab (GC-1008)TGFβ1,-β2,-β3Targets all isoforms of TGFβNCT01284322

FG-3019CCN2Anti-CTGF, reduces the number of CD45-positive cellsBrenner MC et al. [19]

P144TGFβ1Blocks the interaction between TGFβ1 and TGFβ1 type III receptorNCT00574613,
Postlethwaite AE et al. [20]

Anti-Integrin V6 (Abituzumab)TGFβInhibits binding to αv heterodimers, preventing TGF-β activationNCT02745145,
Katsumoto et al. [17],
Henderson NC et al. [21]

PirfenidoneTNFα, IL1β, TGFβBlocks TGF-β-stimulated collagen synthesisUdwadia ZF et al. [22]
Khanna D et al. [23]

Nintedanib
(BIBF 1120)
VEGF, PDGF, FGFTKI-targeting FGF, PDGF, and VEGF receptors, as well as Src-family tyrosine kinasesNCT02597933,
Distler et al. [24]

Treatments against vascular alterations

Bosentan,
Macitentan
ETA/ETB receptorBlocks both ETA and ETB endothelin receptors that mediate the effects of ET-1NCT00077584,
Matucci-Cerinic M et al. [25]
NCT00660179,
Metha S et al. [26]

AmbrisentanETA receptorBlocks the action of endothelin-1 at the ETA receptorNCT00091598,
NCT01178073,
Gailè N et al. [27],
Raghu G et al. [28]

SelexipagIP receptorSelective IP prostacyclin receptor agonist for long-term treatment of PAHSitbon O et al. [29],
Denton CP et al. [30]

RiociguatGMPc agonistSoluble guanylate cyclase (sGC) modulator with both vasoactive and antifibrotic effectsNCT02283762,
NCT00863681

Bardoxolone methylNrf2 and NF-κBActivation of Nrf2 and inhibition of NF-κBNCT02036970,
NCT02657356

To perform this literature review, we conducted a research through electronic resources (PubMed, ScienceDirect, Nature, Elsevier, BMJ, and Wiley Online), reviewing references in the English language from the last 10 years. We identified articles via general search of the terms “systemic sclerosis OR scleroderma” and “systemic sclerosis pathogenesis;” the first search yielded 6334 articles, which were handpicked according to relevance that was determined according to the article’s date of publication, ranging from 2008 to October 2018, and its direct relation to scleroderma pathogenesis and directed therapies. Subsequently, we directed a specific search of the terms “Bosentan”, “Macitentan”, “Ambrisentan”, “Selexipag”, “Riociguat”, “bardoxolone methyl”, “Infliximab”, “Adalimumab”, “Rituximab”, “Basiliximab”, “Efalizumab”, “Abatacept”, “AIMSPRO”, “Tocilizumab”, “AM095”, “SAR100842”, “Imatinib”, “Dasatinib”, “Nilotinib”, “CAT-192”, “GC-1008”, “FG-3019”, “P144”, “αvβ6 integrin”, “Pirfenidone”, and “Nintedanib”, which resulted in a range of 2 to 300 references per term.

2. Etiopathogenesis of Systemic Sclerosis and Therapeutic Targets

The triggering factors that unleash the pathogenic processes that lead to the development of systemic sclerosis have not been yet identified. The most accepted working hypothesis implies that, in a genetically susceptible subject, a triggering event occurs (probably exposure to an infectious or environmental agent such as vinyl chloride or silica, or an event that supposes an important immunological challenge such as a pregnancy or the development of a neoplasia), which causes the activation of various cells of the immune system, the endothelium, and the extracellular matrix. These cells then lead to inflammation, fibrosis, and endothelial damage that cannot be counterbalanced by the natural resolution mechanisms of inflammatory processes and scarring (Figure 1).

2.1. Involvement of the Immune System

The most acknowledged evidence of the participation of the immune system in this disease is the presence of various autoantibodies, several of which are present exclusively in this disease and are associated with clinical complications and specific phenotypes as has been broadly described by Dr. Thomas A. Medsger Jr. and his work team [1].

Furthermore, several genetic studies have found, as additional evidence, an association of different gene polymorphisms related to the immune response with the predisposition to suffer systemic sclerosis. Some of the most important ones are polymorphisms in genes of the major histocompatibility complex [8], in regulatory genes of types I and II interferons, in genes of cytokines and chemokines, and of Toll-like receptors (TLR) [9].

Skin from SSc patients shows inflammatory infiltrates in which macrophages, T lymphocytes, and dendritic cells are the predominant cell types [31]. These cells produce cytokines and chemokines with proinflammatory and profibrotic activities, and it is very possible that they participate in the process of endothelium-mesenchymal and epithelial-mesenchymal transition, processes by which endothelial and epithelial cells are activated and acquire characteristics similar to myofibroblasts [10]. The powerful signals generated by cytokines and chemokines also produce the recruitment of bone marrow cells and fibrocytes from the peripheral circulation for their subsequent activation into fibroblasts that will produce collagen and other extracellular matrix proteins that predominate in the fibrotic phase of this disease (Figure 1).

2.1.1. Innate Immune System

Although the factors that promote the persistent activation of cells of the immune system are unknown, recent studies of various groups have pointed towards the Toll-like receptors as possibly responsible for interacting with their classical agonists or with other exogenous or endogenous agonists from damaged tissue to activate dendritic cells, which could secrete proinflammatory cytokines and present antigens to the T cells to activate them. Overexpression of TLR4 and TLR2 has been found in skin and fibroblasts of patients with SSc [32, 33]. On the other hand, the TLR3, TLR7, TLR8, and TLR9, generally viral nucleic acid sensors, could be involved in inflammation in systemic sclerosis; Farina et al. [10] demonstrated the association between Epstein-Barr virus infection, overexpression of interferon-associated genes, transforming growth factor-beta (TGFβ), and other markers of fibroblast activation. In this sense, persistent damage after a viral infection could cause chronic inflammation and fibrosis in susceptible subjects. Activation of dendritic cells through TLRs generally leads to the production of several proinflammatory cytokines, particularly type I interferons, which have been found overexpressed in peripheral blood in patients with systemic sclerosis (interferon signature) [34].

In fact, nearly 50% of SSc patients show the so-called “interferon signature” in peripheral blood and sera [35]. These abnormalities are seen in some SSc patients even at early phases of the disease, before skin fibrosis is well established. In this group of patients, the type I IFN signature in peripheral monocytes correlates with inflammation and fibrosis mediators (B cell activating factor (BAFF) expression and type III procollagen N-terminal propeptide serum levels) [36], which suggests an association between abnormal activation of the IFN-I signaling pathway and disease activity [37].

The consequences of increased type I IFN expression in SSc are diverse and affect immune and endothelial cell function as well as fibroblasts. These effects have been extensively reviewed by Ciechomska and Skalska [38] and are outlined below.

IFN type I effects on immune cells include increased monocyte activation, as well as increased differentiation, survival, proliferation, and activation of T, B, and dendritic cells [10, 36, 3841]. Moreover, Kim et al. showed that serum of SSc patients containing anti-topoisomerase I antibodies induces the production of interferon-alpha by PBMCs cocultured with nuclear extracts. This was particularly higher when they used serum from dcSSc patients and from SSc patients with lung fibrosis [42].

On the other hand, type I IFN effects on endothelial cells include the increased expression of MxA (marker of type I IFN activity) and interferon regulatory factors (IRGs), which correlate with the presence of digital ischemic ulcers [43, 44]. Also, human dermal microvascular endothelial cells (HDMVECs) and fibroblasts stimulated with IFNα and IFNγ show increased vessel permeability, increased expression of alpha smooth muscle actin (α-SMA), connective tissue growth factor (CTGF), transforming growth factor beta 2 (TGF-β2), and endothelin 1 (ET-1), via downregulation of friend leukemia integration 1 transcription factor (Fli1) and downregulation of vascular endothelial cadherin (VE-cadherin) [45].

Finally, type I IFN stimulates the expression of TLRs on DCs and fibroblasts; this leads to increased inflammatory cytokine production by fibroblasts. For instance, type I IFN induces fibroblasts to increase IP-10 production, a profibrotic chemokine that has been associated with severe SSc subtypes [46, 47]. Additionally, positive feedback has been demonstrated between type I IFN and TLR expression, since TLR3 stimulation with its ligand poly I:C also induces upregulation of type I IFNs and IFNα2 responsive genes on fibroblasts [48, 49].

It is also known that the number of plasmacytoid dendritic cells (pDCs) is increased in the circulation of SSc patients, and they secrete large amounts of CXCL4 [50], a chemokine associated with transition from epithelial to mesenchymal cells, the activation of endothelial cells, inhibition of regulatory T cells, and induction of Th17 cells.

On the same line, a murine model showed that IL-33, an alarmin of the IL-1 family related to inflammation and fibrosis, favours IL-13-dependent lung fibrosis [51]. Another group showed that TLR4-deficient mice developed less tissue fibrosis, decreased polarization of Th17 responses, and decreased TGF-β in the bleomycin-induced fibrosis and the tight skin models [52]. It is unknown whether IL-33 can induce fibrosis by this or another pathway in SSc patients.

One of these pathways could be the production of profibrotic cytokines by type 2 innate lymphoid cells. Proliferation and function of these cells are stimulated by exposure to cytokines with epithelial alarmin function such as IL-33 and IL-25, both elevated in patients with systemic sclerosis, and they can produce profibrotic cytokines (IL-4 and IL-13), so they could participate in the pathogenesis of this disease. There is controversial evidence on the abundance and relevance of these cells in patients with systemic sclerosis [53, 54]; however, in a murine model of pulmonary fibrosis it was found that the IL-13 derived from these cells increases the deposit of collagen by the fibroblasts and induces the differentiation of macrophages towards a profibrotic phenotype [55].

Evidence of the involvement of macrophages in the pathogenesis of systemic sclerosis is extensive. Infiltrates of CD68+ cells (macrophage marker) CD163+, CD204+ and an M2 macrophage markers panel were found in the perivascular regions and between the collagen fibers of patients with SSc. Increased CD14+CD163+CD204+ cells have also been found in peripheral blood of patients with SSc, as well as increased markers of macrophage migration and activation (CCL18 and CD163) in microarrays of lung tissue from patients with progressive pulmonary fibrosis [41]. Macrophages can also be stimulated through TLRs and their activation, particularly that of so-called M2 or “alternatively activated” macrophages, would lead to the production of profibrotic substances such as IL-13, TGFβ, platelet-derived growth factor (PDGF), and chemokines such as CCL19 which stimulates the activation of macrophages.

2.1.2. Adaptive Immune System

T lymphocytes are also found in inflammatory infiltrates in tissues of patients with SSc; they display higher expression of activation markers and there is evidence indicating that they express a rather oligoclonal repertoire of T cell receptors, suggesting an antigen-mediated expansion [56]. Th2 cells, producing IL-4 and IL-13, and Th17, producing IL-17, have been found to be increased in both skin and peripheral blood of patients with SSc, particularly in patients with the diffuse form of the disease. The cytokines they produce have important profibrotic and proinflammatory functions; it is likely that these cells are activated by antigen-presenting cells such as dendritic cells [57]. The role of regulatory T cells is less clear since several studies have shown controversial results, but given that it is a very small population of cells, it is possible that its function and regulation, rather than its number, is what is found altered in this and other autoimmune diseases.

B cells, on the other hand, are the producers of the autoantibodies characteristic of this disease, but we also know that these cells infiltrate tissues and show increased activation markers such as CD19, CD21, costimulatory molecules, and B cell activating factor (BAFF). There is evidence in murine models that overexpression of CD19 induces the production of cutaneous fibrosis and that the absence of B cells is associated with decreased fibrosis [58].

2.2. Targeted Therapies for Inflammatory Process
2.2.1. Type I Interferon Modulation

Interferons are pleiotropic cytokines that play a fundamental role as factors responsible for the immune response, mainly in bacterial and viral infections; however, they have also been strongly associated with the pathogenesis of SSc because of their notorious correlation with skin thickness and disease activity when found in elevated levels in patients’ blood and sera [38]. Consequently, several clinical trials have been executed in order to test the potential benefits on directed anti-IFN treatments, as follows:

(1) Anifrolumab    Type I Interferon Receptor. Displaying promising results, anifrolumab is an investigational human IgG1κ monoclonal antibody that has been tested on a phase I trial to treat SSc [59]. According to Peng et al., this drug blocks the formation of the ternary IFN/IFNAR1/IFNAR2 signaling complex by sterically inhibiting the binding of IFN ligands to IFNAR1 [60]. At the same time, regarding SSc patients, this antibody’s safety profile is considered favorable because of the mild to moderate adverse events triggered by it, which include upper respiratory tract infection, headache, diarrhea, and nausea [61].

(2) MEDI7734    Anti-ILT7. Recently AstraZeneca conducted a phase I study of MEDI7734 on a human monoclonal antibody that binds to and causes temporary depletion of plasmacytoid dendritic cells (pDCs) in which the safety, drug levels, and pDC levels in patients with type I IFN-mediated autoimmune diseases were evaluated. pDCs are one of the main type I IFN sources [62]. No results have been published yet.

2.2.2. Rituximab → CD20

Rituximab is a chimeric monoclonal antibody (mAb) that targets CD20, which is expressed from pre-B cell stage to the pre-plasma cell stage [63]. In systemic sclerosis, there is evidence that suggests this drug has an antifibrotic effect [64], as well as potential to improve inflammatory alterations [65] and lung function [66], which characterize several SSc manifestations.

According to Giuggioli’s literature review, after six months of rituximab treatment in patients with either lcSSc or dcSSc, there was clear improvement of both articular and skin SSc manifestations, as well as a safety profile and tolerance; more specifically, it has been documented that the number of swollen and tender joints was markedly reduced after treatment, skin sclerosis improved significantly (specially in patients with diffuse cutaneous involvement), and, similarly, other skin and joint manifestations mitigated, such as melanodermia, pruritus, calcinosis, and arthritis [65].

2.2.3. Basiliximab → IL-2Rα

Basiliximab is a chimeric mAb directed against the α chain (CD25) of the IL-2 receptor that has recently been proposed for the treatment of SSc based on the latest discoveries regarding the crucial role of effector T cells in this disease, particularly Th-17 and T regulatory subsets [67].

As stated by Schmidt et al., skin involvement, lung fibrosis disease progression, and mortality in systemic sclerosis could be ameliorated by the treatment with this drug, since they are strongly correlated with serum levels of soluble IL-2 receptor [68]; regarding side-effects, the ones recorded are mostly minor and, in general, therapy with basiliximab was well tolerated in an open-label SSc study [11].

2.2.4. Efalizumab → LFA1/ICAM-1

The binding of leucocyte function associated antigen 1 (LFA-1) to intracellular adhesion molecule 1 (ICAM-1) is a key step in the migration of T lymphocytes through the endothelial lining of the vascular system during inflammation in skin disorders [69]. In the presence of efalizumab, a humanized recombinant IgG1 monoclonal antibody, the α-subunit of LFA-1 (CD11a) is targeted; thus, the interaction between LFA-1 and ICAM-1 is blocked, hence hindering T-cell’s activation, migration into the skin, and cytotoxic functions [12]. This mechanism of action seems attractive for systemic sclerosis treatment, since increased numbers of T lymphocytes are usually found in dermal infiltrates in this disease. Currently, efalizumab is approved to ameliorate the size and severity of skin lesions in patients with psoriasis, and it has shown sustained long-term response [70]. No SSc clinical trials have been published.

2.2.5. Abatacept → CTLA4

Abatacept is a recombinant CTLA4Ig fusion protein that inhibits T-cell activation by selectively modulating costimulation [13] as it binds to CD80 or CD86 on the T-cell surface.

It has been approved for the treatment of arthritis [71], and it is proposed that its effects on inhibition of T-cell activation may be efficacious in dcSSc [67]. There is also evidence that suggests that this drug could be safe and effective in patients with refractory polyarthritis secondary to scleroderma [13, 72].

2.2.6. AIMSPRO (®) → αMSH, IL10, CCL2

Otherwise known as hyperimmune caprine serum, AIMSPRO is a polyclonal antibody that contains mainly caprine immunoglobulins as well as cytokines, including IL-4 and IL-10, proopiomelanocortin, arginine vasopressin, β-endorphin, and corticotropin-releasing factor [14]. This drug could potentially modulate serum levels of relevant cytokines.

Results in Quillinan’s trial on AIMSPRO treatment in scleroderma showed potential benefit in skin tightness in late cases as well as improvement in overall pain, which is presumably of clinical importance since pain related to tissue ischaemia, inflammation, and intermittent release of neuropathic mediators, presumptively. The drug’s safety profile was adequate, and it was well tolerated [14].

2.2.7. Tocilizumab → IL-6R

Tocilizumab is a monoclonal antibody to the IL-6 receptor [71] that has been tested for diverse SSc clinical manifestations, since an increased production of IL-6 in fibroblasts isolated from the affected skin of SSc patients has been documented [73].

This pleiotropic cytokine has several significant roles in hematopoiesis, inflammation, and immune homeostasis, as well as in T-cell growth and differentiation; there is also evidence that elevated levels of IL-6 are present in other fibrotic diseases such as keloid scars and lung fibrosis, among others.

According to Ong et al., recent findings suggest that therapeutic intervention in fibrotic pathways could be viable by IL-6 modulation, in addition to being a useful tool to promote immune tolerance in systemic sclerosis because of its regulatory effect in the balance between Th17 and Tregs [67].

Regarding clinical effectiveness, there is evidence that this drug highly improves joint parameters after five months of treatment, as well as skin involvement [74]; it has been reported to be effective in refractory polyarthritis and myopathy [75]. Recent evidence in a phase 3 double-blinded clinical trial suggested mild skin improvement and stabilization of lung involvement [76].

2.2.8. AM095 and SAR100842 → LPA1

Lysophosphatidic acid (LPA) is a phospholipid growth factor that targets specific G-protein-coupled receptors that have recently been associated with the pathogenesis of systemic sclerosis. It is generated at inflammation sites or cell damage via autotaxin on lysophosphatidylcholine and other lysophospholipids [77] and could possibly contribute to excessive tissue fibrosis, primarily through the activation of the LPA 1 receptor [78].

SAR100842 is a low molecular weight, orally available selective inhibitor of LPA 1 receptor that aims to ameliorate or even revert fibrotic progression in SSc [79]. According to Allanore’s research, there is important mRSS score improvement after 24 weeks of treatment, which is of clinical significance; and it is an overall well tolerated drug in dcSSc patients, with mild to moderate in intensity adverse effects [79]. There is also evidence that SAR 100842 lowers expression of fibrosis-related genes in scleroderma skin fibroblasts [71].

2.2.9. TAK242 → TLR4

As previously stated, TLR4 stimulation promotes the production of Th1 and Th17 cytokines, and increased levels of this molecule and its ligands have been found in SSc patients. Dr. Varga research group has elegantly shown that TLR4 inhibition with TAK242 prevents and induces regression of experimental fibrosis in bleomycin-induced fibrosis and in TSK/+ mice. His findings suggest that TAK242 might represent a therapeutic strategy for the treatment of SSc and other fibrotic diseases [15].

2.2.10. Inebilizumab → Anti-CD19

Also referred to as MEDI-551, it is a humanized, affinity-optimized, and afucosylated monoclonal antibody that binds to CD19 [80]. In 2014 a phase I clinical trial regarding the safety and tolerability of this drug was completed, in which Schiopu et al. determined that B-cell depletion should be further studied because of its significance regarding the pathogenesis of the disease along with inebilizumab’s pharmacodynamics, which could potentially become a highly beneficial disease-modifying treatment in SSc [81].

2.3. Fibrosis

Fibrosis is the most prominent clinical feature of systemic sclerosis and, largely, the process that leads to the deterioration of the organs’ function affected by the disease. It occurs because of excess production of collagen and other extracellular matrix proteins in the connective tissue of various organs.

Myofibroblasts, the main cells responsible for the production of the extracellular matrix in this disease, can have different origins. It has been suggested that they may come from endothelial cells (endothelium-mesenchymal transdifferentiation), from epithelial cells (epithelial-mesenchymal transdifferentiation), from bone marrow stem cells, from circulating fibrocytes, from fibroblasts already resident in tissues, and from resident stem cells in skin and subcutaneous cellular tissue [82].

Endothelium to mesenchymal transdifferentiation has been elegantly studied by Dr. Sergio Jiménez and his group [82]. In summary, it is proposed that the endothelial cell of a susceptible subject would be subjected to some initial insult that could be the presence of autoantibodies, reactive oxygen species, hypoxia, viral antigens, or own neoantigens; this initial insult would cause the abnormal activation of endothelial cells, which would undergo a transformation that would lead them to express more alpha smooth muscle actin (αSMA), vimentin and type I collagen, and lower amount of cadherin and von Willebrand factor (vWF), converting them into collagen-producing cells similar to myofibroblasts (Figure 1).

The epithelium has a very important role in the repair of injuries; in patients with systemic sclerosis there is evidence that the process of epithelial regeneration is altered. We know that there are many factors derived from the epithelium that influence the behavior of fibroblasts; particularly endothelin 1 (ET-1) and TGF-β have profibrotic activity. There is evidence that the epithelial to mesenchymal transdifferentiation process occurs in pulmonary fibrosis and that both ET-1 and TGF-β participate in this process [83]. During epithelial-mesenchymal transdifferentiation, epithelial cells lose their intercellular junctions and change their polarity, different surface markers are expressed, and there may be remodeling of their cytoskeleton to express a mesenchymal phenotype. Some in vitro studies have shown that alveolar epithelial cells can be transdifferentiated to mesenchymal cells [84]. In addition, some studies in murine models have shown that alveolar epithelial cells can coexpress markers of both epithelial cells and mesenchymal cells, including cadherin and α-SMA [85]. Another evidence in this sense is that, in the murine model of pulmonary fibrosis induced by bleomycin, pulmonary fibrosis is preceded by epithelial damage. This evidence suggests that epithelial damage is important in the pathogenesis of systemic sclerosis, at least for some organs, such as in pulmonary fibrosis and, most likely, the skin.

Regardless of their origin, we know that fibroblasts have different functional phenotypes according to their location (dermis, subcutaneous cellular tissue, lungs, etc.) and can be distinguished by their gene expression profile and their functional activity. Depending on their microenvironment, they can produce different amounts of procollagen, fibronectin, proteases, collagenases, and other regulators of the extracellular matrix. For example, inactive fibroblasts express ET-1 and intracellular adhesion molecules 1 (ICAM-1), whereas fibroblasts exposed to mechanical stress in the microenvironment, a situation that occurs in systemic sclerosis, express α-SMA, TGF-β, and genes associated with the production of extracellular matrix proteins. This phenotype is like that of fibroblasts exposed to an excess of TGF-β signaling [86].

Likewise, it is known that during different phases of tissue repair after a lesion fibroblasts of different origin produce different amounts and types of collagen that influence this process and that could be altered in patients with SSc [87].

2.4. Targeted Therapies for Fibrosis
2.4.1. Imatinib, Dasatinib, Nilotinib → c-Abl, c-Kit, PDGF

Imatinib is a tyrosine kinase inhibitor (TKI) capable of blocking both PDGF and TGF-β signalling pathways. It showed antifibrotic effects in SSc experimental models and then it was evaluated in small clinical trials [16]. Dasatinib and nilotinib, which are second-generation TKIs with higher affinity to Bcr-Abl, and their ability to block c-abl and PDGF were also evaluated for the treatment of dermal fibrosis in vitro and in murine models with promising results [17].

Initial studies showed that low-dose imatinib had an adequate safety profile and a better tolerability than at high doses in the long term for SSc patients [74]. Furthermore, while it had no significant effects on skin involvement in a phase II pilot study, it was effective when used to stabilize lung function in patients with SSc-ILD [88].

2.4.2. CAT-192 → TGFβ1

Also known as metelimumab, CAT-192 is a human recombinant IgG monoclonal antibody that specifically counteracts the TGF-ß1 isoform in SSc. Despite its potential benefit via the inhibition of TGF-ß1, a multicenter, randomized, placebo-controlled phase I/II trial using this drug proved no efficacy and significant side effects, including mortality in patients that received the active treatment [18].

2.4.3. Fresolimumab → TGFβ1,-β2,-β3

Otherwise called GC-1008, fresolimumab is a monoclonal antibody that, unlike metelimumab, can target all isoforms of TGFβ and has yielded very promising results in SSc.

Patients treated with this drug generally display expeditious declines in mRSS scores and infiltration of myofibroblasts into the dermis, as well as in TGFβ-regulated genes’ expression [74]. Bleeding is the main side effect that was recorded in the initial trial [89].

2.4.4. FG-3019 → CCN2

FG3019 is a specific IgG1κ monoclonal antibody to CTGF that has shown potential in decreasing lung fibrosis and scarring according to recent research; however, no specific trials have been conducted in SSc [19].

Treatment with FG-3019 is highly efficient in reducing the number of CD45-positive cells; it also has an antifibrotic effect similar to the genetic deletion of CTGF in collagen-producing cells, which ameliorates angiotensin II-induced skin fibrosis as well as inflammation [7].

2.4.5. P144 → TGFβ1

Peptide 144 is the acetic salt of a 14-mer peptide from human TGFβ1 type III receptor that was precisely designed to block the interaction between TGFβ1 and TGFβ1 type III receptor, consequently inhibiting its biological effects [90].

This drug has shown important antifibrotic activity in mice receiving repeated subcutaneous injections of bleomycin; however, P144 is still undergoing investigations regarding the treatment of skin fibrosis in patients with SSc [20].

2.4.6. Anti-Integrin αVβ6 (Abituzumab) → TGFβ Activation

The integrin αVβ6 is a LAP-binding integrin, mostly expressed in epithelial cells adjacent to wounds [91], that is involved in the initiation of fibrosis and inflammation by TGFβ activity. It promotes activation and differentiation of fibroblasts into myofibroblasts, which causes abnormal extracellular matrix deposition, leading to the destruction of tissue architecture, scarring, and reduced function [92]. Truncation of this integrin’s cytoplasmic tail (associating with the cytoskeleton) prevents latent TGF-β1 activation, thus suppressing the fibrotic process [93].

More precisely, evidence from preclinical models of lung, kidney, and liver fibrosis proposes that inhibition of αVβ6-mediated TGF-β activation could potentially be useful to attend to multiple fibrotic disorders in humans [91] since specifically targeting αvβ6 may reduce the risk of interfering with the beneficial homeostatic control of inflammation and immunity in the treatment of tissue fibrosis [94].

No clinical studies have been completed in this pathway at this time. However, it has been reported by Henderson et al. that V integrins collectively regulate the key profibrotic pathways during organ fibrosis [21]. Indeed, overexpression of integrin αV consequently leads to TGF-β overactivation in SSc dermal fibroblasts because of miR-29’s involvement as a modulator of integrin’s genes implicated in this pathway, as well as miR-142-3p, which directly regulates the expression of integrin αV, as stated by Li et al. [95], whose work is supported by Taniguchi’s epigenetic study on bleomycin-induced skin fibrosis Fli-1 +/- mice, which proved latent TGF-β activation to be an αVβ3 integrin- and αVβ5 integrin-dependent mechanism [96].

Regarding directed therapies on this pathway, abituzumab is a novel, humanized monoclonal IgG2 antibody to the αv subunit that inhibits binding to αv heterodimers, preventing ECM attachment, cell motility, and apoptosis, without cross-reacting with other integrins, which is elemental in inhibiting TGF-β, a key mediator of fibrosis [97]. According to the Clinical Trials registry, there was an ongoing randomized clinical trial on this drug which was recently terminated due to difficulties in enrolling subjects under the eligibility criteria, not allowing for completion of the study within a reasonable time-frame [98].

2.4.7. Pirfenidone → TNFα, IL1β, TGFβ

Pirfenidone is an orally active pyridone small molecule with known anti-inflammatory, antifibrotic, and antioxidant properties that has proven to reduce fibroblast proliferation and block TGF-β-stimulated collagen synthesis; it has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis, disease in which it was associated with modest improvement in function (IPF) [22].

According to Xiao, pirfenidone attenuates lung fibrosis by interfering with the hedgehog signaling pathway in SSc-ILD lung fibroblasts [99]; and consistent with the LOTUSS trial, it has an acceptable tolerability and safety profile in patients with SSc-IP [23]. Scleroderma Lung Study III, a pirfenidone clinical trial for SSc-ILD, is currently ongoing, and it will shed light on the possible indication of pirfenidone for this disease.

2.4.8. Nintedanib → VEGF, PDGF, FGF

Nintedanib, also known as BIBF 1120, is a TKI targeting fibroblast growth factor (FGF) receptor, PDGF receptor, and vascular endothelial growth factor (VEGF) receptor, as well as Src-family tyrosine kinases [71], that is characterized by its broad spectrum of profibrotic targets, which likely offers additive effects as compared with selective inhibition of individual profibrotic molecules [100].

As stated by Varga et al., there is evidence that this drug reduces dermal microvascular endothelial cell apoptosis and modulates the pulmonary vascular restoration by its effect on the number of vascular smooth muscle cells [73]; similarly, it has been confirmed to block proliferation and transformation of human lung fibroblasts, as well as collagen synthesis in skin fibroblasts from SSc patients [58]. A clinical trial involving this molecule is currently ongoing (SENSCIS study) [24].

2.5. Vasculopathy

Raynaud’s phenomenon and vasculopathy associated with it, renal crises, and pulmonary arterial hypertension (PAH) are the classic vascular manifestations of scleroderma. Without a doubt, the endothelium plays a very important role in the initiation and perpetuation of vascular damage in this disease.

It is known that the endothelial damage that occurs from early stages in SSc could lead to 3 paths:(1)Endothelial cell apoptosis, which can lead to blood vessel destruction, that decreased blood flow seen as capillary loss in capillaroscopy(2)Endothelial to mesenchymal transdifferentiation explained previously(3)Endothelial cell “activation,” which refers to overexpression of chemotactic and vasoconstrictor substances such as ICAM-1, vascular adhesion molecule 1 (VCAM-1), E-selectin, and endothelin-1 (ET-1) on endothelial cell surface, leading to vasoconstriction and subendothelial fibrosis, as this process contributes to the development of intraluminal thrombosis and proliferation of the muscular layers, typical characteristics of vasculopathy in systemic sclerosis [82]

Another prominent process in systemic sclerosis, as a reaction to the loss of blood vessel function and hypoxia, is neoangiogenesis. In SSc patients, angiogenesis is abnormal. Angiogenic factors such as PDGF, VEGF and its receptors, ET-1, TGF-β, the monocyte chemoattractant protein 1 (MCP-1), and the urokinase-type plasminogen activator receptors are upregulated, despite the lack of adequate angiogenic responses in ischemic tissues in patients with SSc [101]. Likewise, counter-regulatory factors such as angiostatin and endostatin are persistently increased. The regulation of these systems in patients with SSc is not completely understood.

The generalized vasculopathy in this disease has 2 variants of particular interest: the thrombotic microangiopathy that develops during renal crisis and is histologically indistinguishable from the changes produced in malignant hypertension and the plexiform lesions produced in the advanced phases of pulmonary arterial hypertension.

2.6. Targeted Therapies for Vascular Damage
2.6.1. Bosentan, Macitentan → ETA/ETB Receptor

PAH has been treated for a long time now by using either bosentan or macitentan, two currently approved ERAs, which block both ETA and ETB endothelin receptors that mediate the detrimental effects of ET-1 in this particular disease in which the ET pathway plays a very important role [102].

Bosentan has higher affinity towards ETB receptors and essentially the same affinity for the ETA receptors, and it occupies the orthosteric site of the receptor to block the action of ET-1 by sterically preventing the inward movement of transmembrane helix six of the ETB receptor [103], mechanism that is expected to be preserved in the ETA subtype. Aside from PAH, it has also been proven to reduce the number of new digital ulcers, even in patients with multiple ones, regardless of usage of calcium channel blockers, PDE-5 inhibitors or iloprost therapy, having a highly evident effect in patients with four or more digital ulcers at baseline in the RAPIDS-2 trial. Its effectiveness indicated no difference in either of the disease’s subsets [25].

On the other hand, macitentan was designed to have improved efficacy and higher potency and selectivity over bosentan, and according to Davenport et al., that advantage is due to a longer receptor occupancy [26, 103]. Additionally, pharmacokinetic data have demonstrated that macitentan and its active metabolite both have a long elimination half-life of approximately 16 and 48 hours, respectively, which supports a once-daily dosing regimen [104]. It has been approved in more than 55 countries for the long-term treatment of patients with PAH as monotherapy or in combination with other PAH therapies, as was studied in the SERAPHIN Trial [26].

There have also been several studies regarding both drugs’ efficacy on the fibrotic component of the disease, more specifically, pulmonary fibrosis with modest results [105].

2.6.2. Ambrisentan → ETA Receptor

Ambrisentan, which is meant to block the action of endothelin-1 at the ETA receptor, has been approved for the treatment of pulmonary arterial hypertension [106]. This selective ETA antagonist was developed in an effort to allow vasodilation at the same time that vasoconstriction is being targeted. The pivotal trials ARIES-1, ARIES-2 [27], and AMBITION [107] proved its long-term benefit in idiopathic and SSc-associated PAH patients.

Regarding pulmonary fibrosis, ambrisentan has not shown positive outcomes and is probably associated with an increased risk for disease progression [28], according to Raghu et al.

2.6.3. Selexipag → IP Receptor Agonist

Selexipag is an oral, selective IP prostacyclin receptor agonist that has recently been approved for the long-term treatment of PAH [29]. Due to its high selectivity, its pharmacokinetic properties, and the treatment regime that is followed, selexipag is considered to have a rather reliable safety profile, with minimal adverse effects, ranging from mild to moderate in severity, considering those associated with prostacyclin use [108]. Moreover, oral selexipag has been noted to afford wide dosing flexibility, which might enable reaching the maximum therapeutic effect with acceptable tolerability in patients.

Regarding Raynaud’s phenomenon, there has been no evidence that suggests that this drug has a particular effect on reducing the number of attacks [30], as shown by Denton et al.

2.6.4. Riociguat → GMPc Agonist

Riociguat is a soluble guanylate cyclase (sGC) modulator with both vasoactive and antifibrotic effects. It is currently under evaluation for skin involvement in dcSSc patients in the RISE-SSc trial [109]. It was approved to be used for the treatment of pulmonary arterial hypertension. Its safety and efficacy were established in the PATENT studies [110]. It is important to note that, according to the PATENT-2 trial, survival of patients with PAH associated with connective tissue diseases (PAH-CTD) was similar to that seen in patients with idiopathic/familial PAH after over 2 years of treatment, which is an important observation, as mortality for PAH-CTD has been previously reported to be higher than IPAH despite modern therapy, which indicates this drug’s tolerability and satisfactory clinical response.

2.6.5. Bardoxolone Methyl → Nrf2 and NF-κB

Bardoxolone methyl is a semisynthetic triterpenoid that upregulates antioxidant responses and suppresses proinflammatory signaling to reduce oxidative stress and inflammation and promote mitochondrial function, through activation of Nrf2 (nuclear factor erythroid derived 2-related factor 2) and inhibition of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) [111]. It is currently being tested to treat several pathologies including pulmonary arterial hypertension, cancer, and kidney diseases [112].

Preliminary results from the extension of the LARIAT study, a phase 2 study to evaluate the safety of bardoxolone methyl in PAH patients with different causes (NCT02036970), which included some patients with PAH-CTD, showed good tolerance and sustained improvement in 6-minute walk test (6MWT) for up to 32 weeks [113].

CATALYST is a phase 3, double-blinded, placebo-controlled study to assess the safety and efficacy of bardoxolone methyl relative to placebo in patients with connective tissue disease-associated pulmonary arterial hypertension, to determine the change from baseline in 6-minute walk distance (6MWD) following 24 weeks of study participation (NCT02657356). This study started in October of 2016 and it is still active; it should be completed by mid-2020.

3. Conclusions

Systemic sclerosis is an autoimmune disease of unknown etiology. There are still many questions in its pathogenesis, particularly in the complex regulation of inflammatory and fibrotic processes, and in the factors that trigger its onset. Research efforts in this regard will allow finding more effective treatments, directed against therapeutic targets suitable for the different phases and complications of this condition.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

  1. T. A. Medsger Jr, T. S. Rodríguez-Reyna, and R. T. Domsic, “Clasificación e historia natural de la esclerosis sistémica,” in Esclerosis Sistémica, chapter 11, pp. 187–197, Elsevier Editorial, Masson Doyma, Mexico, 1st edition, 2009. View at: Google Scholar
  2. O. Kowal-Bielecka, J. Fransen, J. Avouac et al., “Update of EULAR recommendations for the treatment of systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1327–1339, 2017. View at: Publisher Site | Google Scholar
  3. D. Mukerhee, D. St George, B. Colerio et al., “Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach,” Annals of the Rheumatic Diseases, vol. 9, Article ID 209909, pp. 1088–1093, 2003. View at: Publisher Site | Google Scholar
  4. M. R. Fisher, S. C. Mathai, H. C. Champion et al., “Clinical differences between idiopathic and scleroderma-related pulmonary hypertension,” Arthritis & Rheumatology, vol. 54, no. 9, pp. 3043–3050, 2006. View at: Publisher Site | Google Scholar
  5. R. Condliffe, D. G. Kiely, A. J. Peacock et al., “Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 2, pp. 151–157, 2009. View at: Publisher Site | Google Scholar
  6. S. I. Nihtyanova, E. C. Tang, J. G. Coghlan, A. U. Wells, C. M. Black, and C. P. Denton, “Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: A retrospective cohort study,” QJM: An International Journal of Medicine, vol. 103, no. 2, Article ID hcp174, pp. 109–115, 2009. View at: Publisher Site | Google Scholar
  7. C. P. Denton, “Systemic sclerosis: from pathogenesis to targeted therapy,” Clinical and Experimental Rheumatology, vol. 33, Supplement 92, pp. S3–S7, 2015. View at: Google Scholar
  8. T. S. Rodriguez-Reyna, P. Mercado-Velázquez, N. Yu et al., “HLA Class I and II Blocks Are Associated to Susceptibility, Clinical Subtypes and Autoantibodies in Mexican Systemic Sclerosis (SSc) Patients,” PLoS ONE, vol. 10, no. 5, Article ID e0126727, 2015. View at: Publisher Site | Google Scholar
  9. P. Fuschiotti, “Current perspectives on the immunopathogenesis of systemic sclerosis,” ImmunoTargets and Therapy, vol. 5, pp. 21–35, 2016. View at: Google Scholar
  10. A. Farina, M. Cirone, M. York et al., “Epstein-barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in Scleroderma,” Journal of Investigative Dermatology, vol. 134, no. 4, pp. 954–964, 2014. View at: Publisher Site | Google Scholar
  11. M. O. Becker, C. Brückner, H. U. Scherer et al., “The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: An open-label study,” Annals of the Rheumatic Diseases, vol. 70, no. 7, pp. 1340-1341, 2011. View at: Publisher Site | Google Scholar
  12. T. Zimmerman and F. J. Blanco, “Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action,” Current Pharmaceutical Design, vol. 14, no. 22, pp. 2128–2139, 2008. View at: Publisher Site | Google Scholar
  13. M. Elhai, M. Meunier, M. Matucci-Cerinic et al., “Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: A EUSTAR observational study,” Annals of the Rheumatic Diseases, vol. 72, no. 7, pp. 1217–1220, 2013. View at: Publisher Site | Google Scholar
  14. N. P. Quillinan, D. McIntosh, J. Vernes, S. Haq, and C. P. Denton, “Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial,” Annals of The Rheumatic Diseases, vol. 73, no. 1, pp. 56–61, 2013. View at: Publisher Site | Google Scholar
  15. S. Bhattacharyya, W. Wang, Z. Tamaki et al., “Pharmacological inhibition of toll-like receptor-4 signaling by tak242 prevents and induces regression of experimental organ fibrosis,” Frontiers in Immunology, vol. 9, Article ID 02434, 2018. View at: Publisher Site | Google Scholar
  16. N. Iwamoto, J. H. W. Distler, and O. Distler, “Tyrosine kinase inhibitors in the treatment of systemic sclerosis: From animal models to clinical trials,” Current Rheumatology Reports, vol. 13, no. 1, pp. 21–27, 2011. View at: Publisher Site | Google Scholar
  17. A. Akhmetshina, C. Dees, M. Pileckyte et al., “Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis,” The FASEB Journal, vol. 22, no. 7, pp. 2214–2222, 2008. View at: Publisher Site | Google Scholar
  18. C. P. Denton, P. A. Merkel, D. E. Furst et al., “Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192,” Arthritis & Rheumatology, vol. 56, no. 1, pp. 323–333, 2007. View at: Publisher Site | Google Scholar
  19. M. C. Brenner, W. Krzyzanski, J. Z. Chou et al., “FG-3019, a human monoclonal antibody recognizing connective tissue growth factor, is subject to target-mediated drug disposition,” Pharmaceutical Research, vol. 33, no. 8, pp. 1833–1849, 2016. View at: Publisher Site | Google Scholar
  20. A. E. Postlethwaite, L. J. Harris, S. H. Raza, S. Kodura, and T. Akhigbe, “Pharmacotherapy of systemic sclerosis,” Expert Opinion on Pharmacotherapy, vol. 11, no. 5, pp. 789–806, 2010. View at: Publisher Site | Google Scholar
  21. N. C. Henderson, T. D. Arnold, Y. Katamura et al., “Targeting of integrin identifies a core molecular pathway that regulates fibrosis in several organs,” Nature Medicine, vol. 19, no. 12, pp. 1617–1624, 2013. View at: Publisher Site | Google Scholar
  22. Z. F. Udwadia, J. B. Mullerpattan, C. Balakrishnan, and L. Richeldi, “Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis,” Lung India, vol. 32, no. 1, pp. 50–52, 2015. View at: Publisher Site | Google Scholar
  23. D. Khanna, C. Albera, A. Fischer et al., “An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial,” The Journal of Rheumatology, vol. 43, no. 9, pp. 1672–1679, 2016. View at: Publisher Site | Google Scholar
  24. O. Distler, K. K. Brown, J. H. W. Distler et al., “Design of a randomized, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS),” Clinical and Experimental Rheumatology, vol. 106, Supplement 35, no. 4, pp. 75–81, 2017. View at: Google Scholar
  25. M. Matucci-Cerinic, C. P. Denton, D. E. Furst et al., “Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial,” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 32–38, 2011. View at: Publisher Site | Google Scholar
  26. S. Mehta, B. K. Sastry, R. Souza et al., “Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled seraphin trial,” CHEST, vol. 151, no. 1, pp. 106–118, 2017. View at: Publisher Site | Google Scholar
  27. N. Galiè, H. Olschewski, R. J. Oudiz et al., “Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2,” Circulation, vol. 117, no. 23, pp. 3010–3019, 2008. View at: Publisher Site | Google Scholar
  28. G. Raghu, J. Behr, K. K. Brown et al., “Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial,” Annals of Internal Medicine, vol. 158, no. 9, pp. 641–649, 2013. View at: Publisher Site | Google Scholar
  29. O. Sitbon, R. Channick, K. M. Chin et al., “Selexipag for the treatment of pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 373, no. 26, pp. 2522–2533, 2015. View at: Publisher Site | Google Scholar
  30. C. P. Denton, É. Hachulla, G. Riemekasten et al., “Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study,” Arthritis & Rheumatology, vol. 69, no. 12, pp. 2370–2379, 2017. View at: Publisher Site | Google Scholar
  31. A. D. Roumm, T. L. Whiteside, T. A. Medsger, and G. P. Rodnan, “Lymphocytes in the skin of patients with progressive systemic sclerosis,” Arthritis & Rheumatism, vol. 27, no. 6, pp. 645–653, 1984. View at: Publisher Site | Google Scholar
  32. S. Bhattacharyya, K. Kelley, D. S. Melichian et al., “Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma,” The American Journal of Pathology, vol. 182, no. 1, pp. 192–205, 2013. View at: Publisher Site | Google Scholar
  33. S. Bhattacharyya and J. Varga, “Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis,” Current Rheumatology Reports, vol. 17, no. 1, article 474, 2015. View at: Publisher Site | Google Scholar
  34. F. K. Tan, X. Zhou, M. D. Mayes et al., “Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients,” Rheumatology, vol. 45, no. 6, pp. 694–702, 2006. View at: Publisher Site | Google Scholar
  35. S. Assassi, M. D. Mayes, F. C. Arnett et al., “Systemic sclerosis and lupus: Points in an interferon-mediated continuum,” Arthritis & Rheumatology, vol. 62, no. 2, pp. 589–598, 2010. View at: Publisher Site | Google Scholar
  36. Z. Brkic, L. Van Bon, M. Cossu et al., “The interferon type i signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis,” Annals of the Rheumatic Diseases, vol. 75, no. 8, pp. 1567–1573, 2016. View at: Publisher Site | Google Scholar
  37. B. W. Higgs, Z. Liu, B. White et al., “Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway,” Annals of the Rheumatic Diseases, vol. 70, no. 11, pp. 2029–2036, 2011. View at: Publisher Site | Google Scholar
  38. M. Ciechomska and U. Skalska, “Targeting interferons as a strategy for systemic sclerosis treatment,” Immunology Letters, vol. 195, pp. 45–54, 2018. View at: Publisher Site | Google Scholar
  39. J. M. González-Navajas, J. Lee, M. David, and E. Raz, “Immunomodulatory functions of type i interferons,” Nature Reviews Immunology, vol. 12, no. 2, pp. 125–135, 2012. View at: Publisher Site | Google Scholar
  40. M. R. York, T. Nagai, A. J. Mangini, R. Lemaire, J. M. Van Seventer, and R. Lafyatis, “A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists,” Arthritis & Rheumatology, vol. 56, no. 3, pp. 1010–1020, 2007. View at: Publisher Site | Google Scholar
  41. G. Farina, D. Lafyatis, R. Lemaire, and R. Lafyatis, “A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis,” Arthritis & Rheumatology, vol. 62, no. 1, pp. 580–588, 2010. View at: Publisher Site | Google Scholar
  42. D. Kim, A. Peck, D. Santer et al., “Induction of interferon-α by scleroderma sera containing autoantibodies to topoisomerase I: Association of higher interferon-α activity with lung fibrosis,” Arthritis & Rheumatology, vol. 58, no. 7, pp. 2163–2173, 2008. View at: Publisher Site | Google Scholar
  43. P. Airò, C. Ghidini, C. Zanotti et al., “Upregulation of myxovirus-resistance protein A: A possible marker of type I interferon induction in systemic sclerosis,” The Journal of Rheumatology, vol. 35, no. 11, pp. 2192–2200, 2008. View at: Publisher Site | Google Scholar
  44. C. L. Bos, L. G. M. van Baarsen, T. C. G. Timmer et al., “Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers,” Genes & Immunity, vol. 10, no. 3, pp. 210–218, 2009. View at: Publisher Site | Google Scholar
  45. I. Chrobak, S. Lenna, L. Stawski, and M. Trojanowska, “Interferon-γ promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) β2,” Journal of Cellular Physiology, vol. 228, no. 8, pp. 1774–1783, 2013. View at: Publisher Site | Google Scholar
  46. M.-L. Eloranta, K. Franck-Larsson, T. Lövgren et al., “Type I interferon system activation and association with disease manifestations in systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1396–1402, 2010. View at: Publisher Site | Google Scholar
  47. A. Corrado, “The Th1 chemokine IP-10 in systemic sclerosis,” La Clinica Terapeutica, vol. 165, no. 6, pp. e436–e441, 2014. View at: Publisher Site | Google Scholar
  48. S. K. Agarwal, M. Wu, C. K. Livingston et al., “Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts,” Arthritis Research & Therapy, vol. 13, no. 1, article no. R3, 2011. View at: Publisher Site | Google Scholar
  49. J. Wei, S. Bhattacharyya, W. G. Tourtellotte, and J. Varga, “Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy,” Autoimmunity Reviews, vol. 10, no. 5, pp. 267–275, 2011. View at: Publisher Site | Google Scholar
  50. L. van Bon, A. J. Affandi, J. Broen et al., “Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis,” The New England Journal of Medicine, vol. 370, no. 5, pp. 433–443, 2014. View at: Publisher Site | Google Scholar
  51. D. Li, R. Guabiraba, A.-G. Besnard et al., “IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice,” The Journal of Allergy and Clinical Immunology, vol. 134, no. 6, pp. 1422–1432, 2014. View at: Publisher Site | Google Scholar
  52. T. Takahashi, Y. Asano, Y. Ichimura et al., “Amelioration of Tissue Fibrosis by Toll-like Receptor 4 Knockout in Murine Models of Systemic Sclerosis,” Arthritis & Rheumatology, vol. 67, no. 1, pp. 254–265, 2015. View at: Publisher Site | Google Scholar
  53. F. Roan, T. A. Stoklasek, E. Whalen et al., “CD4+ group 1 innate lymphoid cells (ILC) form a functionally distinct ILC subset that is increased in systemic sclerosis,” The Journal of Immunology, vol. 196, no. 5, pp. 2051–2062, 2016. View at: Publisher Site | Google Scholar
  54. T. Wohlfahrt, S. Usherenko, M. Englbrecht et al., “Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis,” Annals of the Rheumatic Diseases, vol. 75, no. 3, pp. 623–626, 2016. View at: Publisher Site | Google Scholar
  55. E. Hams, M. E. Armstrong, J. L. Barlow et al., “IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 111, no. 1, pp. 367–372, 2014. View at: Publisher Site | Google Scholar
  56. L. I. Sakkas, B. Xu, C. M. Artlett, S. Lu, S. A. Jimenez, and C. D. Platsoucas, “Oligoclonal T cell expansion in the skin of patients with systemic sclerosis,” The Journal of Immunology, vol. 168, no. 7, pp. 3649–3659, 2002. View at: Publisher Site | Google Scholar
  57. T. S. Rodŕguez-Reyna, J. Furuzawa-Carballeda, J. Cabiedes et al., “Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study,” Rheumatology International, vol. 32, no. 9, pp. 2653–2660, 2012. View at: Publisher Site | Google Scholar
  58. M. Hasegawa, Y. Hamaguchi, K. Yanaba et al., “B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis,” The American Journal of Pathology, vol. 169, no. 3, pp. 954–966, 2006. View at: Publisher Site | Google Scholar
  59. ClinicalTrials.gov, S. Yoo, and MD: National Library of Medicine (US), “A Phase 1 Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of MEDI-546, a Fully Human Monoclonal Antibody Directed Against Subunit 1 of the Type I Interferon Receptor, in Adult Subjects With Scleroderma,” Identifier NCT00930683, 2012, https://clinicaltrials.gov/ct2/show/NCT00930683. View at: Google Scholar
  60. L. Peng, V. Oganesyan, H. Wu, W. F. Dall'Acqua, and M. M. Damschroder, “Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody,” mAbs, vol. 7, no. 2, pp. 428–439, 2015. View at: Publisher Site | Google Scholar
  61. A. Goldberg, T. Geppert, E. Schiopu et al., “Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: A phase 1, multicenter, open label study,” Arthritis Research & Therapy, vol. 16, no. 1, article no. R57, 2014. View at: Publisher Site | Google Scholar
  62. ClinicalTrials.gov and MedImmune LLC: National Library of Medicine (US), “A Phase 1, Randomized, Blinded, Single-Dose, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases,” Identifier NCT02780674, 2018, https://clinicaltrials.gov/ct2/show/NCT02780674. View at: Google Scholar
  63. S. J. ordan, J. H. Distler, B. Maurer et al., “Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group,” Annals Of The Rheumatic Diseases, vol. 74, no. 6, pp. 1188–1194, 2015. View at: Google Scholar
  64. S. Bosello, M. De Santis, G. Lama et al., “B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial,” Arthritis Research & Therapy, vol. 12, article no. R54, no. 2, 2010. View at: Publisher Site | Google Scholar
  65. D. Giuggioli, F. Lumetti, M. Colaci, P. Fallahi, A. Antonelli, and C. Ferri, “Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature,” Autoimmunity Reviews, vol. 14, no. 11, pp. 1072–1078, 2015. View at: Publisher Site | Google Scholar
  66. V. Smith, J. T. Van Praet, B. Vandooren et al., “Rituximab in diffuse cutaneous systemic sclerosis: An open-label clinical and histopathological study,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 193–197, 2010. View at: Publisher Site | Google Scholar
  67. V. H. Ong and C. P. Denton, “Innovative therapies for systemic sclerosis,” Current Opinion in Rheumatology, vol. 22, no. 3, pp. 264–272, 2010. View at: Publisher Site | Google Scholar
  68. K. Schmidt, L. Martinez-Gamboa, S. Meier et al., “Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients,” Arthritis Research & Therapy, vol. 11, no. 4, article R111, 2009. View at: Publisher Site | Google Scholar
  69. K. R. Carson, D. Focosi, E. O. Major et al., “Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) Project,” The Lancet Oncology, vol. 10, no. 8, pp. 816–824, 2009. View at: Publisher Site | Google Scholar
  70. M. Talamonti, G. Spallone, A. Di Stefani, A. Costanzo, and S. Chimenti, “Efalizumab,” Expert Opinion on Drug Safety, vol. 10, no. 2, pp. 239–251, 2011. View at: Publisher Site | Google Scholar
  71. D. Khanna, J. H. Distler, P. Sandner, and O. Distler, “Emerging strategies for treatment of systemic sclerosis,” Journal of Scleroderma and Related Disorders, vol. 1, no. 2, pp. 186–193, 2016. View at: Google Scholar
  72. M. Elhai, J. Avouac, A. Kahan, and Y. Allanore, “Systemic sclerosis: Recent insights,” Joint Bone Spine, vol. 82, no. 3, pp. 148–153, 2015. View at: Publisher Site | Google Scholar
  73. J. Varga, C. P. Denton, and F. M. Wigley, “Mechanisms of Fibrosis,” in Scleroderma: From Pathogenesis to Comprehensive Management, J. Varga, Ed., Springer, 2012. View at: Google Scholar
  74. S. Barsotti, C. Stagnaro, and A. Della Rossa, “Systemic sclerosis: a critical digest of the recent literature,” Clinical and Experimental Rheumatology, vol. 33, supplement 91, pp. S3–S14, 2015. View at: Google Scholar
  75. A. Young and D. Khanna, “Systemic Sclerosis—A systematic review on therapeutic management from 2011–2014,” Current Opinion In Rheumatology, vol. 27, no. 3, p. 241, 2015. View at: Google Scholar
  76. D. Khanna, C. J. F. Lin, M. Kuwana et al., “Efficacy and Safety of Tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial,” in Proceedings of the 2018 ACR/ARHP Annual Meeting, vol. 898, 2018. View at: Google Scholar
  77. Y. Zhao and V. Natarajan, “Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling,” Biochimica et Biophysica Acta, vol. 1831, pp. 86–92, 2013. View at: Google Scholar
  78. J. S. Swaney, C. Chapman, L. D. Correa et al., “Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist,” The Journal Of Pharmacology And Experimental Therapeutics, vol. 336, no. 3, pp. 693–700, 2011. View at: Publisher Site | Google Scholar
  79. Y. Allanore, O. Distler, A. Jagerschmidt et al., “Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis,” Arthritis & Rheumatology, vol. 70, no. 10, pp. 1634–1643, 2018. View at: Publisher Site | Google Scholar
  80. K. Streicher, S. Sridhar, M. Kuziora et al., “Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI‐551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease,” Arthritis & Rheumatology, vol. 70, no. 12, pp. 2087–2095, 2018. View at: Publisher Site | Google Scholar
  81. E. Schiopu, S. Chatterjee, V. Hsu et al., “Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study,” Arthritis Research & Therapy, vol. 18, no. 1, 2016. View at: Publisher Site | Google Scholar
  82. S. A. Jimenez, “Role of Endothelial to Mesenchymal Transition in the Pathogenesis of the Vascular Alterations in Systemic Sclerosis,” ISRN Rheumatology, vol. 2013, Article ID 835948, 15 pages, 2013. View at: Publisher Site | Google Scholar
  83. R. Jain, P. W. Shaul, Z. Borok, and B. C. Willis, “Endothelin-1 Induces Alveolar Epithelial–Mesenchymal Transition through Endothelin Type A Receptor–Mediated Production of TGF-β1,” American Journal of Respiratory Cell and Molecular Biology, vol. 37, no. 1, pp. 38–47, 2007. View at: Publisher Site | Google Scholar
  84. B. C. Willis, R. M. DuBois, and Z. Borok, “Epithelial origin of myofibroblasts during fibrosis in the lung,” Proceedings of the American Thoracic Society, vol. 3, no. 4, pp. 377–382, 2006. View at: Publisher Site | Google Scholar
  85. K. K. Kim, M. C. Kugler, P. J. Wolters et al., “Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 103, no. 35, pp. 13180–13185, 2006. View at: Publisher Site | Google Scholar
  86. S. Sonnylal, C. P. Denton, B. Zheng et al., “Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma,” Arthritis & Rheumatology, vol. 56, no. 1, pp. 334–344, 2007. View at: Publisher Site | Google Scholar
  87. R. R. Driskell, B. M. Lichtenberger, E. Hoste et al., “Distinct fibroblast lineages determine dermal architecture in skin development and repair,” Nature, vol. 504, no. 7479, pp. 277–281, 2013. View at: Publisher Site | Google Scholar
  88. P. Fraticelli, B. Gabrielli, G. Pomponio et al., “Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study,” Arthritis Research & Therapy, vol. 16, article no. R144, no. 4, 2014. View at: Google Scholar
  89. L. M. Rice, C. M. Padilla, S. R. McLaughlin et al., “Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients,” The Journal of Clinical Investigation, vol. 125, no. 7, pp. 2795–2807, 2015. View at: Publisher Site | Google Scholar
  90. ClinicalTrials.gov and Matucci (MD): National Library of Medicine (US), “Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis,” Identifier NCT00574613, 2007, https://clinicaltrials.gov/ct2/show/NCT00574613. View at: Google Scholar
  91. S. L. Nishimura, “Integrin-mediated transforming growth factor-β activation, a potential therapeutic target in fibrogenic disorders,” The American Journal of Pathology, vol. 175, no. 4, pp. 1362–1370, 2009. View at: Publisher Site | Google Scholar
  92. R. J. Akhurst and A. Hata, “Targeting the TGFβ signalling pathway in disease,” Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 790–811, 2012. View at: Publisher Site | Google Scholar
  93. B. Hinz, “Tissue stiffness, latent TGF-β1 Activation, and mechanical signal transduction: Implications for the pathogenesis and treatment of fibrosis,” Current Rheumatology Reports, vol. 11, no. 2, pp. 120–126, 2009. View at: Publisher Site | Google Scholar
  94. T. R. Katsumoto, S. M. Violette, and D. Sheppard, “Blocking TGFβ via inhibition of the αvβ6 integrin: a possible therapy for systemic sclerosis interstitial lung disease,” International Journal Of Rheumatology, vol. 2011, Article ID 208219, 7 pages, 2011. View at: Publisher Site | Google Scholar
  95. Y. Li, J. Huang, M. Guo, and X. Zuo, “MicroRNAs Regulating Signaling Pathways: Potential Biomarkers in Systemic Sclerosis,” Genomics, Proteomics & Bioinformatics, vol. 13, no. 4, pp. 234–241, 2015. View at: Publisher Site | Google Scholar
  96. T. Taniguchi, Y. Asano, K. Akamata et al., “Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice,” Arthritis & Rheumatology, vol. 67, no. 2, pp. 517–526, 2015. View at: Publisher Site | Google Scholar
  97. D. Khanna, D. P. Tashkin, C. P. Denton, M. W. Lubell, C. Vazquez-Mateo, and S. Wax, “Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease,” Rheumatology, 2018. View at: Publisher Site | Google Scholar
  98. ClinicalTrials.gov and EMD Serono Inc: National Library of Medicine (US), “Abituzumab in SSc-ILD,” Identifier NCT02745145, 2018, https://clinicaltrials.gov/ct2/show/NCT02745145. View at: Google Scholar
  99. H. Xiao, G. F. Zhang, X. P. Liao et al., “Anti‐fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease,” International Journal Of Rheumatic Diseases, vol. 21, no. 2, pp. 477–486, 2018. View at: Publisher Site | Google Scholar
  100. J. Huang, C. Beyer, K. Palumbo-Zerr et al., “Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis,” Annals of the Rheumatic Diseases, vol. 75, no. 5, pp. 883–890, 2016. View at: Publisher Site | Google Scholar
  101. O. Distler, J. H. W. Distler, A. Scheid et al., “Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis,” Circulation Research, vol. 95, no. 1, pp. 109–116, 2004. View at: Publisher Site | Google Scholar
  102. P. Jansa and T. Pulido, “Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial,” American Journal of Cardiovascular Drugs, vol. 18, no. 1, pp. 1–11, 2018. View at: Publisher Site | Google Scholar
  103. A. P. Davenport, R. E. Kuc, C. Southan, and J. J. Maguire, “New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine,” Physiological Research, vol. 67, Supplement 1, no. 1-9, pp. S37–S54, 2018. View at: Google Scholar
  104. S. Bruderer, G. Hopfgartner, M. Seiberling et al., “Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans,” Xenobiotica, vol. 42, no. 9, pp. 901–910, 2012. View at: Publisher Site | Google Scholar
  105. B. Rochwerg, B. Neupane, Y. Zhang et al., “Treatment of idiopathic pulmonary fibrosis: A network meta-analysis,” BMC Medicine, vol. 14, no. 1, article no. 18, 2016. View at: Publisher Site | Google Scholar
  106. A. J. Peacock, W. Zamboni, and C. D. Vizza, “Ambrisentan for the treatment of adults with pulmonary arterial hypertension: A review,” Current Medical Research and Opinion, vol. 31, no. 9, pp. 1793–1807, 2015. View at: Publisher Site | Google Scholar
  107. N. Galie, J. A. Barbera, A. E. Frost et al., “Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 373, no. 9, pp. 834–844, 2015. View at: Publisher Site | Google Scholar
  108. J. H. Pérez, “Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review,” Expert Review of Clinical Pharmacology, vol. 10, no. 7, pp. 753–762, 2017. View at: Publisher Site | Google Scholar
  109. O. Distler, J. Pope, C. Denton et al., “RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis,” Respiratory Medicine, vol. 122, pp. S14–S17, 2017. View at: Publisher Site | Google Scholar
  110. M. Humbert, J. G. Coghlan, H.-A. Ghofrani et al., “Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: Results from PATENT-1 and PATENT-2,” Annals of the Rheumatic Diseases, vol. 76, no. 2, pp. 422–426, 2017. View at: Publisher Site | Google Scholar
  111. M. B. Sporn, K. T. Liby, M. M. Yore, L. Fu, J. M. Lopchuk, and G. W. Gribble, “New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress,” Journal of Natural Products, vol. 74, no. 3, pp. 537–545, 2011. View at: Publisher Site | Google Scholar
  112. S. Zhou, Y. Wang, H. Zhe, Y. Yang, and Z. He, “Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties,” Drug Design, Development and Therapy, vol. 8, pp. 2075–2088, 2014. View at: Publisher Site | Google Scholar
  113. R. Oudiz, C. Meyer, M. Chin et al., “Bardoxolone methyl produces durable benefits in participants with pulmonary arterial hypertension: data from an open-label extension study,” in Proceedings of the Poster 844 at the 2016 ACR/ARHP Annual Meeting, vol. 148, 2016. View at: Publisher Site | Google Scholar

Copyright © 2019 Andrea Sierra-Sepúlveda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

6494 Views | 2004 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.